Timothy J Voorhees, MD

Timothy J Voorhees, MD

Physician

Specialty:Hematology

Gender: Male

Academic Title: Assistant Professor in the College of Medicine

Research Program: Translational Therapeutics

  • I am an assistant professor in the Division of Hematology at The Ohio State University and a member of the Translational Therapeutics Program at the OSUCCC —– James. My research is focused on enhancing treatments that improve survival rates and quality of life for patients with blood cancers. I am currently serving as the principal investigator on a project funded by the Lymphoma Research Foundation. My team and I are developing and implementing a phase Ib trial of epcoritamab for relapsed or refractory post-transplant lymphoproliferative disorder. My research has been widely published in peer-reviewed journals, and I am often invited to present my work at annual meetings and conferences. I am an editorial board member for Frontiers in Hematology and Frontiers in Immunology. I am also involved with professional organizations including the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Society of Hematology.

    • Non-Hodgkin Lymphoma
    • Hematology
    • Lymphomas
    • Hodgkin Lymphoma
  • Medical School

    • Ohio State University College of Medicine
      370 W 9Th Ave, Columbus, OH

    Residency - Internal Medicine

    • Ohio State University Wexner Medical Center
      700 Ackerman Rd, Columbus, OH

    Fellowship

    • UNC Hospitals
      101 Manning Dr, Chapel Hill, NC

    Fellowship - Hematology & Oncology

    • UNC Hospitals
      101 Manning Dr, Chapel Hill, NC
  • Academic Office:

    The James Outpatient Care 7258
    2121 Kenny Rd
    Columbus, Ohio 43221

  • October 22, 2024

    Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis.

    Bajwa A, Zhao Q, Geer MJ, Lin C, Westholder J, Maakaron J, Ghosh M, Frame DG, Galal A, Tossey J, Ahmed N, Bezerra ED, Denlinger N, de Lima MJ, Epperla N, Caimi PF, Voorhees TJ

    Blood Adv

    May 1, 2024

    Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.

    Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla N

    Hematol Oncol

    March 23, 2024

    Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.

    Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y

    Blood Adv

    March 18, 2024

    SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.

    Voorhees TJ, Bezerra E, Denlinger N, Jaglowski S, de Lima M

    Clin Lymphoma Myeloma Leuk

  • At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Voorhees has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

    • Genmab
    • Recordati
    • ADC Therapeutics
    • AbbVie